ARTO trial (NCT03449719): Long-term overall survival analysis from a randomized phase II trial testing the benefit of stereotactic body radiotherapy addition to abiraterone acetate in oligometastatic ...
We report phase I results for obrixtamig (BI 764532), a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager, in patients with previously treated DLL3-positive small cell lung cancer (SCLC), ...
Peluntamig (PT217) targets DLL3 and CD47, receiving FDA orphan drug and fast track designations for SCLC and NEC. The SKYBRIDGE trial evaluates peluntamig's safety, tolerability, and efficacy in ...
Neuroendocrine carcinomas (NECs), which include small-cell lung cancer (SCLC), are a highly heterogeneous group of aggressive cancers with poor prognosis, noted Martin Wermke, MD, of TU Dresden ...
DUBLIN--(BUSINESS WIRE)--The "DLL3 Targeted Therapies Market, Approved Drugs, Dosage, Pricing & Clinical Trials Insight 2025" report has been added to ResearchAndMarkets.com's offering. Delta-like ...
Please provide your email address to receive an email when new articles are posted on . MADRID — A novel T-cell engager appeared safe and exhibited efficacy as treatment for neuroendocrine tumors, ...
Molecular Partners announced positive IND-enabling data for MP0712 and preclinical findings for novel targeted Radio-DARPins at AACR 2025. Molecular Partners AG announced positive IND-enabling data ...
A new imaging technique developed at Memorial Sloan Kettering Cancer Center (MSK) shows promise for detecting deadly forms of lung cancer and prostate cancer. The technology uses a radioactive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results